Indiana 2022 Regular Session

Indiana Senate Bill SB0209

Introduced
1/6/22  
Refer
1/6/22  
Report Pass
1/20/22  
Engrossed
2/2/22  
Refer
2/7/22  
Report Pass
2/17/22  

Caption

Drug schedules.

Impact

If enacted, SB 209 will have a significant impact on state laws regarding drug enforcement and classification. By adding specific synthetic substances to the controlled substance schedules, the bill seeks to close loopholes that may allow these drugs to be sold legally despite their potential harm. This legislative action reflects an awareness of the evolving drug landscape and aims to provide law enforcement with the tools needed to combat the distribution of dangerous drugs effectively.

Summary

Senate Bill 209 aims to amend the Indiana Code concerning criminal law and procedure, specifically in relation to the classification of synthetic drugs and the substances that are considered controlled. The bill adds specified synthetic substances to the list of controlled substances, which includes various chemical compounds. It also urges a thorough study of delta-8 THC and related psychoactive cannabinoids during the legislative interim. The intent of this bill is to address the growing concerns over synthetic drugs and ensure that the law is up-to-date with current substances that may pose risks to health and safety.

Sentiment

The sentiment regarding SB 209 appears to be generally supportive among legislators who recognize the necessity of updating drug laws to keep pace with emerging threats from synthetic drugs. However, some concerns may arise around the definition of substances and the implications for users and distributors. The call for a further study on delta-8 THC suggests that while there is a desire to regulate, there is also recognition of the need for more information regarding its safety and implications before implementing broad restrictions.

Contention

Notable points of contention surrounding SB 209 include the classification of substances like delta-8 THC, which has garnered attention for its psychoactive properties. The bill's directive to study this compound reflects ongoing debates about its safety and appropriate legal status. As lawmakers navigate these complexities, there is an effort to address public health safety while also considering the ramifications of stringent regulations on users and medical applications of such substances.

Companion Bills

No companion bills found.

Previously Filed As

IN SB0157

Disclosures related to prescription drugs.

IN SB0245

Abortion inducing drugs.

IN SB0118

340B drug program report.

IN SB0282

Compounding drugs; registration of medical spas.

IN HB1328

Charges for hospital administered drugs.

IN SB0136

Disclosures related to prescription drugs.

IN SB0236

Abortion inducing drugs and abortion reports.

IN HB1121

Drug and alcohol testing.

IN SB0191

Electronic record of confidential address.

IN SB0306

Film and media production tax credit.

Similar Bills

No similar bills found.